Travere climbs 6.1% on record FILSPARI sales
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Travere Therapeutics posted third-quarter 2026 revenue of US$224.56 million with record FILSPARI sales, though it booked a net loss of US$52.34 million. New PROTECT Phase 3 biomarker data reinforced FILSPARI's role in rare kidney disease. Analysts hold a $75.21 target versus a $58.88 price, implying 27.7% upside on a 14/1/0 Buy/Hold/Sell split.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.